BioSpace News Archive

The free-to-the-public livestream event will feature insights from former speaker of the House, Newt Gingrich, and biotech investment expert, Marc Lichtenfeld.

Ligand Pharmaceuticals Incorporated and SQ Innovation AG announced that the two companies have entered into long-term, exclusive commercial license and supply agreements for use of Ligand’s Captisol® technology in the formulation of high-concentration furosemide for the treatment of edema in patients with heart failure.

This upgrade, named Project Odyssey, will improve management systems related to process safety and key compliance workflows.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia (VIN).

DTN, the leading provider for actionable weather insights, today announces its expanded partnership with Esri, the world leader in location intelligence

Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, announced that it has been selected by Karyopharm Therapeutics, Inc. to be in the limited distribution network for XPOVIO™ (selinexor).

iSchemaView, the worldwide leader in advanced imaging for stroke, has received registration approval under the Japanese Pharmaceutical Affairs Law through third party review by the Japanese Association for the Advancement of Medical Equipment for its RAPID imaging platform.

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, commercially launched DEXYCU® (dexamethasone intraocular suspension) 9% in March 2019 in the United States. DEXYCU is the first and only U.S. Food and Drug Administration (FDA) approved intraocular steroid

Wize Pharma, Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today that it has retained Lighthouse BioPartners, LLC

According to Coherent Market Insights, the global natural language processing in healthcare and life sciences market was valued at US$ 1,497.89 million in 2018, and is projected to exhibit a CAGR of 26.8% during the forecast period.